Incyte stock price target maintained at $152 by H.C. Wainwright on cancer drug data
Covered in this story
What has happened since
- Incyte is up 3.7% since this was published, 18 days ago.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
Morgan Stanley’s $119 target on $INCY is on the record and being tracked to Oct 2027 (12-month default), scored on the close that day.
Morgan Stanley’s track record →Tracked from this story
UBS’s $127 target on $INCY is on the record and being tracked to Oct 2027 (12-month default), scored on the close that day.
UBS’s track record →Analyst targets on Incyte
- Oppenheimer: at $120 · target $144 by Oct 2027 · Outperform via Investing.com
- H.C. Wainwright: at $125 · target $152 by Sep 2027 · Buy via Investing.com
- Oppenheimer: at $130 · target $120 by Jul 2027 · Perform via Investing.com
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $INCY yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Incyte →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.